These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8653534)

  • 21. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.
    Hill JO; Hauptman J; Anderson JW; Fujioka K; O'Neil PM; Smith DK; Zavoral JH; Aronne LJ
    Am J Clin Nutr; 1999 Jun; 69(6):1108-16. PubMed ID: 10357727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women.
    Bougoulia M; Triantos A; Koliakos G
    Hormones (Athens); 2006; 5(4):259-69. PubMed ID: 17178701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients].
    Sjostrom L; Rissanen A; Andersen T; Boldrin M; Golay A; Koppeschaar H; Krempf M;
    Ter Arkh; 2000; 72(8):50-4. PubMed ID: 11019429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.
    Sjöström L; Rissanen A; Andersen T; Boldrin M; Golay A; Koppeschaar HP; Krempf M
    Lancet; 1998 Jul; 352(9123):167-72. PubMed ID: 9683204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipase inhibition by orlistat: effects on gall-bladder kinetics and cholecystokinin release in obesity.
    Mathus-Vliegen EM; Van Ierland-Van Leeuwen ML; Terpstra A
    Aliment Pharmacol Ther; 2004 Mar; 19(5):601-11. PubMed ID: 14987329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The long-term influence of orlistat on dietary intake in obese subjects with components of metabolic syndrome.
    Svendsen M; Helgeland M; Tonstad S
    J Hum Nutr Diet; 2009 Feb; 22(1):55-63. PubMed ID: 19192027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the inhibition of dietary fat absorption by full versus divided doses of orlistat.
    Hussain Y; Güzelhan C; Odink J; van der Beek EJ; Hartmann D
    J Clin Pharmacol; 1994 Nov; 34(11):1121-5. PubMed ID: 7876405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of single-dose orlistat on postprandial serum glucose, insulin and glucagon-like peptide-1 levels in nondiabetic obese patients.
    Sahin M; Tanaci N; Yucel M; Tutuncu NB; Guvener N
    Clin Endocrinol (Oxf); 2007 Sep; 67(3):346-50. PubMed ID: 17524030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care--correlations with food intake, metabolism, exercise capacity, and hormones.
    Fouladiun M; Körner U; Bosaeus I; Daneryd P; Hyltander A; Lundholm KG
    Cancer; 2005 May; 103(10):2189-98. PubMed ID: 15822132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fat intake and food choices during weight reduction with diet, behavioural modification and a lipase inhibitor.
    Franson K; Rössner S
    J Intern Med; 2000 May; 247(5):607-14. PubMed ID: 10810001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of lipase in the regulation of postprandial gastric acid secretion and emptying of fat in humans: a study with orlistat, a highly specific lipase inhibitor.
    Borovicka J; Schwizer W; Guttmann G; Hartmann D; Kosinski M; Wastiel C; Bischof-Delaloye A; Fried M
    Gut; 2000 Jun; 46(6):774-81. PubMed ID: 10807887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations.
    Ellrichmann M; Kapelle M; Ritter PR; Holst JJ; Herzig KH; Schmidt WE; Schmitz F; Meier JJ
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3995-8. PubMed ID: 18647814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
    Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z
    Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group.
    Van Gaal LF; Broom JI; Enzi G; Toplak H
    Eur J Clin Pharmacol; 1998 Apr; 54(2):125-32. PubMed ID: 9626916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study.
    Drent ML; Larsson I; William-Olsson T; Quaade F; Czubayko F; von Bergmann K; Strobel W; Sjöström L; van der Veen EA
    Int J Obes Relat Metab Disord; 1995 Apr; 19(4):221-6. PubMed ID: 7627244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of a lipase inhibitor (Orlistat) on cholecystokinin and appetite in response to a high-fat meal.
    Goedecke JH; Barsdorf M; Beglinger C; Levitt NS; Lambert EV
    Int J Obes Relat Metab Disord; 2003 Dec; 27(12):1479-85. PubMed ID: 14634678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of short-term treatment with orlistat on growth hormone/insulin-like growth factor-I axis in obese post-menopausal women.
    Di Somma C; Rivellese A; Pizza G; Patti L; De Rosa A; Cipriano P; Nedi V; Rossi A; Lombardi G; Colao A; Savastano S
    J Endocrinol Invest; 2011 Feb; 34(2):90-6. PubMed ID: 21502796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of milk replacer composition on selected blood metabolites and hormones in preweaned Holstein heifers.
    Daniels KM; Hill SR; Knowlton KF; James RE; McGilliard ML; Akers RM
    J Dairy Sci; 2008 Jul; 91(7):2628-40. PubMed ID: 18565922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes.
    Kelley DE; Kuller LH; McKolanis TM; Harper P; Mancino J; Kalhan S
    Diabetes Care; 2004 Jan; 27(1):33-40. PubMed ID: 14693963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of orlistat on bone turnover and body composition.
    Gotfredsen A; Westergren Hendel H; Andersen T
    Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1154-60. PubMed ID: 11486790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.